drugset
drugset / Trial / NCT00030550

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

NCT00030550 ↗

Phase 2 Completed Roswell Park Cancer Institute National Cancer Institute (NCI) · collab
RandomizedDouble-blindTreatment

Summary

RATIONALE: Thalidomide may be an effective treatment for anemia caused by myelodysplastic syndrome. PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating anemia in patients who have myelodysplastic syndrome.

Timeline

Start
2001-09
Primary completion
2003-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified — Oral

Indications

leukemia myelodysplastic syndrome myelodysplastic/myeloproliferative neoplasm